<DOC>
	<DOCNO>NCT02953301</DOCNO>
	<brief_summary>The purpose study determine whether resminostat able delay prevent worsen disease patient advanced stage mycosis fungoides Sézary Syndrome recently achieve disease control previous systemic therapy .</brief_summary>
	<brief_title>Resminostat Maintenance Treatment Patients With Advanced Stage Mycosis Fungoides ( MF ) Sézary Syndrome ( SS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Main Patients histologically confirm MF ( Stage IIBIVB ) SS ongoing complete response ( CR ) , partial response ( PR ) stable disease ( SD ) least one prior systemic therapy accord local standard ( include limit αinterferon , bexarotene , total skin electron beam irradiation , chemotherapy ) [ recent systemic therapy must complete planned stop due unacceptable toxicity 28 week prior randomisation ] Eastern Cooperative Oncology Group ( ECOG ) status score 02 Adequate haematological , hepatic renal function Main Patients progressive disease ( PD ) Baseline correct QT ( QTc ) interval &gt; 500 millisecond Concurrent use specific antitumour therapy include psoralen photo chemotherapy ( PUVA ) , chemotherapy , immunotherapy , hormonal therapy , radiation therapy , experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cutaneous T-Cell Lymphoma ( CTLC )</keyword>
	<keyword>Maintenance</keyword>
	<keyword>resminostat</keyword>
	<keyword>4SC</keyword>
	<keyword>HDAC</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>Sézary Syndrome</keyword>
</DOC>